Clinical evaluation of the ZstatFlu-II test: a chemiluminescent rapid diagnostic test for influenza virus

被引:26
作者
Hamilton, MS
Abel, DM
Ballam, YJ
Otto, MK
Nickell, AF
Pence, LM
Appleman, JR
Shimasaki, CD
Achyuthan, KE
机构
[1] Childrens Mercy Hosp, Dept Pathol, Kansas City, MO 64108 USA
[2] Univ Missouri, Sch Med, Kansas City, MO 64108 USA
[3] ZymeTx Inc, Oklahoma City, OK USA
关键词
D O I
10.1128/JCM.40.7.2331-2334.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Exploiting the high sensitivity of the chemiluminescence phenomenon, an accurate and sensitive point-of-care test, called the ZstatFlu-II test (ZymeTx, Inc., Oklahoma City, Okla.), was developed to detect influenza virus infections. The ZstatFlu-II test takes 20 min and requires approximately 2 min of "hands-on" time for operational steps. The ZstatFlu-II test does not distinguish between infections with influenza virus types A and B. ZstatFlu-II test results are printed on Polaroid High-Speed Detector Film, allowing test results to be archived. A prototype version of the ZstatFlu-II test was evaluated during the 2000-to-2001 flu season with 300 nasal aspirate specimens from children at a pediatric hospital. Compared to culture, the ZstatFlu-II test had 88% sensitivity and 92% specificity. The Directigen test had a sensitivity of 75% and a specificity of 93%. The sensitivity of the ZstatFlu-II test was significantly higher than that of the Directigen test (P < 0.0574).
引用
收藏
页码:2331 / 2334
页数:4
相关论文
共 26 条
[1]   Comparative enzymology, biochemistry and pathophysiology of human exo-α-sialidases (neuraminidases) [J].
Achyuthan, KE ;
Achyuthan, AM .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 2001, 129 (01) :29-64
[2]  
Achyuthan KE, 1998, J BIOLUM CHEMILUM, V13, P1, DOI 10.1002/(SICI)1099-1271(199801/02)13:1<1::AID-BIO460>3.0.CO
[3]  
2-W
[4]  
Boon ACM, 2001, J MED VIROL, V65, P163, DOI 10.1002/jmv.2016
[5]   Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir [J].
Buxton, RC ;
Edwards, B ;
Juo, RR ;
Voyta, JC ;
Tisdale, M ;
Bethell, RC .
ANALYTICAL BIOCHEMISTRY, 2000, 280 (02) :291-300
[6]  
*CDCP ADV COMM IMM, 1999, MMWR-MORBID MORTAL W, V48, P25
[7]   Influenza [J].
Cox, NJ ;
Subbarao, K .
LANCET, 1999, 354 (9186) :1277-1282
[8]  
Fleiss JL, 1981, STATISTICAL METHODS, P211, DOI DOI 10.2307/2530193
[9]  
GALEN RS, 1979, ORTHOP CLIN N AM, V10, P287
[10]   Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients [J].
Griffin, AD ;
Perry, AS ;
Fleming, DM .
PHARMACOECONOMICS, 2001, 19 (03) :293-301